CUMBERLAND, RI – May 05, 2020 – TEDOR Pharma Inc., www.tedorpharma.com a full-service contract development and manufacturing organization (CDMO), today announced that they entered into an agreement to provide cGMP contract manufacturing services for the Center for International Health Research at Rhode Island Hospital. TEDOR will support a clinical trial that will inform the safety and efficacy of Praziquantel for children under the age of four. Currently, these children are not included in treatment campaigns. The selection of TEDOR is expected to provide Rhode Island Hospital with a qualified manufacturing partner for any further developmental requirements.
Jennifer Friedman, MD, PhD stated, “We are pleased to be working with TEDOR on this important project. Their location, capabilities, and facilities are a very good match for our program.”
“We are delighted to partner with Rhode Island Hospital to provide Phase 2 clinical trial manufacturing services,” commented Doug Drysdale, President and CEO of TEDOR Pharma. “Our extensive experience in manufacturing combination products makes TEDOR well suited to provide both clinical trial supply and eventual commercialization.”
About Tedor Pharma, Inc.
Founded in 2001, TEDOR Pharma is a specialized Contract Development and Manufacturing Organization with a strong track record of success in providing development and manufacturing services for oral solid dose products, including DEA-scheduled products, for life science customers. Over nearly two decades, TEDOR has helped customers meet their project timelines, achieve regulatory approvals, and solve formulation challenges. TEDOR offers services ranging from formulation development, clinical trial manufacturing, scale-up and full-scale commercial manufacturing, tech transfer, stability studies, and product life cycle management with patented FLEXITAB™ technology.